Recent News
Read ArticleDespite declining incidence of lupus, mortality for SLE was twice that of controls in this large incident cohort study.
FDA has accepted Genetech application for obinutuzumab (Gazyva) to treat SLE (currently only approved for lupus nephritis) - based on Phase III ALLEGORY study w/ Gazyva showing signif reduced dz activity https://t.co/hgYMJJDKGA https://t.co/41sZkXPM7W
Dr. John Cush @RheumNow ( View Tweet)
DESIR axSpA inception cohort study of 631 pts (no HTN), found no signif association between NSAID use & incident HTN. Over 10 YRs, 88 developed HTN (HR 1.01, 1.00–1.02) https://t.co/Gs9mPwthEj https://t.co/4sfpHmFTsu
Links:
Dr. John Cush @RheumNow ( View Tweet)
Chinese study of 371 pts w/ Autoimmune hepatitis (AIH) - extrahepatic autoimmune diseases (EADs) seen in 24% -Sjogren’s & autoimmune thyroid dz (9% each). ANA+ independently assoc w/ EADs (OR 2) https://t.co/NVz8MWbJch https://t.co/tjCzaDcUFI
Dr. John Cush @RheumNow ( View Tweet)
Comorbidity burden, uveitis, & psoriasis independently assoc w/ greater spinal radiographic progression in AS. Study3,441 pts (75% male; 84% B27+). Progression greater w/ 2+ comorbidities & uveitis, & PSO https://t.co/WDUdjqiD4e https://t.co/nkRCjzSLFT
Dr. John Cush @RheumNow ( View Tweet)
Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM https://t.co/QP8YdX7CcH
Dr. John Cush @RheumNow ( View Tweet)
Rheumatology Salaries 2025
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
https://t.co/UKc2l4FBQZ https://t.co/Kqzbl6pGWh
Dr. John Cush @RheumNow ( View Tweet)
NSAIDs in Inflammatory Bowel Disease?
MedPage Today
At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products can trigger IBD flares.
Read Article
ACR Endorses New Training Model for Pediatric Subspecialties
ACR
The American College of Rheumatology (ACR) welcomes the recent announcement from the American Board of Pediatrics (ABP) outlining new training models for pediatric subspecialties. Given the collaborative work ACR has engaged in over the years, this is an important step forward in reimagining pediatric subspecialty training.
Read Article
Prescribing Lessons (4.17.2026)
https://t.co/6JfMvsGIdS https://t.co/W6BNcwMD3O
Dr. John Cush @RheumNow ( View Tweet)
Severe thrombocytopenia (TP) assoc w/ severe APS & increased mortality. Retro study of 432 #APS pts - 142 w/ TP (33%): 13% severe TP (<50L G/L). Severe TP assoc w/ ITP & CAP -had higher mortality https://t.co/p0bvLKupUe
Dr. John Cush @RheumNow ( View Tweet)
Aspirin Cardiovascular Prevention in Giant Cell Arteritis
A retrospective target trial emulations has shown that low-dose aspirin (ASA) given with a giant cell arteritis (GCA) diagnosis is associated with a lower risk of major adverse cardiovascular events (MACE), but a higher https://t.co/dpGzjKZYkA
Dr. John Cush @RheumNow ( View Tweet)
Weight-loss drugs may affect joints directly
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/xKm8Ng7fXO
Dr. John Cush @RheumNow ( View Tweet)
Rheumatology Salaries 2025
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
The survey included over 5916 physicians from 29 specialties. Rheumatologists made up 1% of the respondents.
What is the most widely shared physician concern regarding the use of augmented intelligence? Take this week's RheumIQ quiz to find out.
https://t.co/SkXNtYJk2v https://t.co/fOKS5clUz5
Links:
Dr. John Cush @RheumNow ( View Tweet)
Aspirin Cardiovascular Prevention in Giant Cell Arteritis
A retrospective target trial emulations has shown that low-dose aspirin (ASA) given with a giant cell arteritis (GCA) diagnosis is associated with a lower risk of major adverse cardiovascular events (MACE), but a higher risk of GI bleeding.
Read Article
Weight-loss drugs may affect joints directly
EulrekAlert!
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis.
Do patients with chronic pain have double the rates of smoking compared to those without pain? Take this week's RheumIQ quiz to find out.
https://t.co/rmB55KC7Zh https://t.co/ms3G9uBMd5
Links:
Dr. John Cush @RheumNow ( View Tweet)
IN 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3:
1. Skyrizi $440 million
2. Tremfya $431 M
3. Rinvoq $376 M
https://t.co/EsWgUqUy9Z https://t.co/zVHdVA2puZ
Dr. John Cush @RheumNow ( View Tweet)
Mevalonate kinase deficiency (AKA hyper-IgD syndr-HIDS) is a rare autosomal recessive autoinflammatory dz of the MVK gene w/ exaggerated innate immunity & incr IL-1β production. Usually Dx in kids, milder forms of periodic fever syndrome have been seen in adults. https://t.co/0hAIz4JgY3
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Prescribing Lessons (4.17.2026)-
Top Four and More (4.10.2026)
-
Whats New PsA? (4.3.2026)
PsA GRAPPA Domains- Outcomes With a JAKi
Therapeutic Updates
PsA GRAPPA domains: Outcomes With a JAKi
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Read Post
Poster Hall
